DanCann Pharma A/S
DanCann Pharma A/S, a biopharmaceutical company, focuses on discovering, developing, manufacturing, and commercializing therapeutic cannabinoids in various disease areas. It sources, develops, and distributes prescription and over-the-counter cannabinoid-based pharmaceuticals primarily focused on pain patients. The company's development pipeline includes EXT02 CannGros, EXT03 CannGros, EXT04 Cann… Read more
DanCann Pharma A/S (DCPXF) - Total Assets
Latest total assets as of December 2024: $15.06 Million USD
Based on the latest financial reports, DanCann Pharma A/S (DCPXF) holds total assets worth $15.06 Million USD as of December 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
DanCann Pharma A/S - Total Assets Trend (2019–2024)
This chart illustrates how DanCann Pharma A/S’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
DanCann Pharma A/S - Asset Composition Analysis
Current Asset Composition (September 2024)
DanCann Pharma A/S's total assets of $15.06 Million consist of 30.3% current assets and 69.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 23.0% |
| Accounts Receivable | $150.00K | 1.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $6.99 Million | 46.4% |
Asset Composition Trend (2019–2024)
This chart illustrates how DanCann Pharma A/S's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: DanCann Pharma A/S's current assets represent 30.3% of total assets in 2024, a decrease from 31.7% in 2019.
- Cash Position: Cash and equivalents constituted 23.0% of total assets in 2024, up from 12.2% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 46.0% of total assets, a decrease from 64.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 46.4% of total assets.
DanCann Pharma A/S Competitors by Total Assets
Key competitors of DanCann Pharma A/S based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
| No similar companies found. | ||
DanCann Pharma A/S - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - DanCann Pharma A/S generates 0.52x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - DanCann Pharma A/S is currently not profitable relative to its asset base.
DanCann Pharma A/S - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.06 | 0.40 | 1.20 |
| Quick Ratio | 3.06 | 0.40 | 1.19 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.07 Million | $ -4.70 Million | $ 3.00 Million |
DanCann Pharma A/S - Advanced Valuation Insights
This section examines the relationship between DanCann Pharma A/S's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.20 |
| Latest Market Cap to Assets Ratio | 2.65 |
| Asset Growth Rate (YoY) | -13.4% |
| Total Assets | $15.06 Million |
| Market Capitalization | $39.87 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values DanCann Pharma A/S's assets at a significant premium ( 2.65x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: DanCann Pharma A/S's assets decreased by 13.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for DanCann Pharma A/S (2019–2024)
The table below shows the annual total assets of DanCann Pharma A/S from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-09-30 | $15.06 Million | -13.41% |
| 2023-09-30 | $17.39 Million | -76.40% |
| 2022-09-30 | $73.69 Million | +6.81% |
| 2021-09-30 | $68.99 Million | +39.24% |
| 2020-09-30 | $49.55 Million | +3264.94% |
| 2019-09-30 | $1.47 Million | -- |